As tislelizum­ab gains trac­tion in Chi­na, BeiGene pulls the cur­tain on NSCLC da­ta sup­port­ing the PD-1 drug

In a world now brim­ming with check­point in­hibitors, com­pa­nies of­ten strug­gle to make a mark giv­en a raft of ther­a­pies have al­ready cap­tured a con­sid­er­able por­tion of the vast on­col­o­gy mar­ket.

BeiGene’s tislelizum­ab was the fourth PD(L)-1 in­hibitor to se­cure ap­proval in Chi­na — and as it works on ex­pand­ing its share the com­pa­ny has put out de­tailed da­ta on the use of the drug in cer­tain pa­tients with lung can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER